NCT00226057View on ClinicalTrials.gov

Efalizumab for Moderate to Severe Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

May 31, 2006

Conditions

Dermatitis, Atopic

Interventions

DRUG

Raptiva

Open Label

All Listed Sponsors

lead

Oregon Health and Science University

OTHER

NCT00226057 - Efalizumab for Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter